http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#Head
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#assertion
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#provenance
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#pubinfo
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#assertion
http://purl.obolibrary.org/obo/DOID_5844
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_5844
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00540
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
http://www.w3.org/2000/01/rdf-schema#label
"The use of nortriptyline hydrochloride or other tricyclic antidepressants concurrently with a monoamine oxidase (MAO) inhibitor is contraindicated. Hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. It is advisable to have discontinued the MAO inhibitor for at least two weeks before treatment with nortriptyline hydrochloride is started. Patients hypersensitive to nortriptyline hydrochloride should not be given the drug. Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00540
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#provenance
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#pubinfo
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig
http://purl.org/nanopub/x/hasSignature
HXF0YGLD/NCgn1AN0B4WB7SzzBQsc8xxY4td3e4BGxyjPuqrwFWf1J5yAHTjjoPHWbAPOK0jKYQUlnDiMVNW4NykzdOFsAPC0xK30UCxtbFFjG/wEUoc75sNJmWfbhI6YmIwuCE95BW5jHZw2dvWtd11cNz0S0mcTQGPUizXDVQ=
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://purl.org/dc/terms/created
2021-08-25T13:35:57.634+02:00
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY